These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9822908)

  • 1. Protective effects of a neurotrophic ACTH(4-9) analog on cisplatin ototoxicity in relation to the cisplatin dose: an electrocochleographic study in albino guinea pigs.
    Stengs CH; Klis SF; Huizing EH; Smoorenburg GF
    Hear Res; 1998 Oct; 124(1-2):108-17. PubMed ID: 9822908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin ototoxicity. An electrophysiological dose-effect study in albino guinea pigs.
    Stengs CH; Klis SF; Huizing EH; Smoorenburg GF
    Hear Res; 1998 Oct; 124(1-2):99-107. PubMed ID: 9822907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of a neuroprotective ACTH(4-9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs.
    Hamers FP; Klis SF; Gispen WH; Smoorenburg GF
    Eur Arch Otorhinolaryngol; 1994; 251(1):23-9. PubMed ID: 8179863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin ototoxicity and the possibly protective effect of alpha-melanocyte stimulating hormone.
    Heijmen PS; Klis SF; De Groot JC; Smoorenburg GF
    Hear Res; 1999 Feb; 128(1-2):27-39. PubMed ID: 10082280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological effects of co-administration of an ACTH((4-9)) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig.
    Cardinaal RM; de Groot JC; Huizing EH; Veldman JE; Smoorenburg GF
    Hear Res; 2000 Jun; 144(1-2):157-67. PubMed ID: 10831874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity.
    Wolters FL; de Vocht TF; Klis SF; Hamers FP; Smoorenburg GF
    Hear Res; 2002 Oct; 172(1-2):110-7. PubMed ID: 12361873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible cisplatin ototoxicity in the albino guinea pig.
    Klis SF; O'Leary SJ; Hamers FP; De Groot JC; Smoorenburg GF
    Neuroreport; 2000 Feb; 11(3):623-6. PubMed ID: 10718325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin.
    de Groot JC; Hamers FP; Gispen WH; Smoorenburg GF
    Hear Res; 1997 Apr; 106(1-2):9-19. PubMed ID: 9112103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perilymphatic application of cisplatin over several days in albino guinea pigs: dose-dependency of electrophysiological and morphological effects.
    O'Leary SJ; Klis SF; de Groot JC; Hamers FP; Smoorenburg GF
    Hear Res; 2001 Apr; 154(1-2):135-45. PubMed ID: 11423224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea.
    Cardinaal RM; de Groot JC; Huizing EH; Veldman JE; Smoorenburg GF
    Hear Res; 2000 Jun; 144(1-2):135-46. PubMed ID: 10831872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic co-treatment with alpha-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs.
    Wolters FL; Klis SF; de Groot JC; Hamers FP; Prieskorn DM; Miller JM; Smoorenburg GF
    Hear Res; 2003 May; 179(1-2):53-61. PubMed ID: 12742238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceleration of cisplatin ototoxicity by perilymphatic application of 4-methylthiobenzoic acid.
    Cappaert NL; Klis SF; Wijbenga J; Smoorenburg GF
    Hear Res; 2005 May; 203(1-2):80-7. PubMed ID: 15855032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin ototoxicity involves organ of Corti, stria vascularis and spiral ganglion: modulation by alphaMSH and ORG 2766.
    Hamers FP; Wijbenga J; Wolters FL; Klis SF; Sluyter S; Smoorenburg GF
    Audiol Neurootol; 2003; 8(6):305-15. PubMed ID: 14566101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perilymphatic application of alpha-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin.
    Wolters FL; Klis SF; Hamers FP; de Groot JC; Smoorenburg GF
    Hear Res; 2004 Mar; 189(1-2):31-40. PubMed ID: 14987750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-induced ototoxicity; electrophysiological evidence of spontaneous recovery in the albino guinea pig.
    Stengs CH; Klis SF; Huizing EH; Smoorenburg GF
    Hear Res; 1997 Sep; 111(1-2):103-13. PubMed ID: 9307316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection and spontaneous recovery from cisplatin-induced hearing loss.
    Smoorenburg GF; De Groot JC; Hamers FP; Klis SF
    Ann N Y Acad Sci; 1999 Nov; 884():192-210. PubMed ID: 10842594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial recovery of cisplatin-induced hearing loss in the albino guinea pig in relation to cisplatin dose.
    Klis SF; O'Leary SJ; Wijbenga J; de Groot JC; Hamers FP; Smoorenburg GF
    Hear Res; 2002 Feb; 164(1-2):138-46. PubMed ID: 11950533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototoxicity resulting from combined administration of cisplatin and gentamicin.
    Riggs LC; Brummett RE; Guitjens SK; Matz GJ
    Laryngoscope; 1996 Apr; 106(4):401-6. PubMed ID: 8614212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study.
    van Ruijven MW; de Groot JC; Klis SF; Smoorenburg GF
    Hear Res; 2005 Jul; 205(1-2):241-8. PubMed ID: 15953532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antioxidants in protection from ototoxic drugs.
    Sergi B; Fetoni AR; Ferraresi A; Troiani D; Azzena GB; Paludetti G; Maurizi M
    Acta Otolaryngol Suppl; 2004 May; (552):42-5. PubMed ID: 15219046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.